Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published October 9, 2008 | Accepted Version + Supplemental Material
Journal Article Open

In vivo activation of midbrain dopamine neurons via sensitized, high-affinity α6*nicotinic acetylcholine receptors

Abstract

α6-containing (α6*) nicotinic ACh receptors (nAChRs) are selectively expressed in dopamine (DA) neurons and participate in cholinergic transmission. We generated and studied mice with gain-of-function α6* nAChRs, which isolate and amplify cholinergic control of DA transmission. In contrast to gene knockouts or pharmacological blockers, which show necessity, we show that activating α6* nAChRs and DA neurons is sufficient to cause locomotor hyperactivity. α6(L9'S) mice are hyperactive in their home cage and fail to habituate to a novel environment. Selective activation of α6* nAChRs with low doses of nicotine, by stimulating DA but not GABA neurons, exaggerates these phenotypes and produces a hyperdopaminergic state in vivo. Experiments with additional nicotinic drugs show that altering agonist efficacy at α6* provides fine tuning of DA release and locomotor responses. α6*-specific agonists or antagonists may, by targeting endogenous cholinergic mechanisms in midbrain or striatum, provide a method for manipulating DA transmission in neural disorders.

Additional Information

© 2008 Elsevier B.V. Accepted 4 September 2008. Published: October 8, 2008. Available online 8 October 2008. We thank members of the Lester lab for helpful discussions. Special thanks to B. Drenan. Thanks to C. Wageman, E. Myers, C. Xiao, A. Tapper, R. Nashmi, C. Fonck, J. Schwarz, J. Jankowsky, M. Liu, P. Deshpande, S. Benazouz, and C. Zhou. This work was supported by H.H.M.I. (N.H., J.M. Miwa, S.B.) and grants from NIH (DA09121, DA17279, and NS11756 to H.A.L.; DA19375 to H.A.L. and M.J.M.; DA03194 to M.J.M.; DA12242 to M.J.M. and P.W.; MH53631 and GM48677 to J.M. McIntosh), the Moore Foundation, the Croll Research Foundation (to J.M. Miwa) and the California Tobacco Related Disease Research Program (TRDRP; 12RT-0245 to H.A.L.). R.M.D. was supported by postdoctoral fellowships from TRDRP (15FT-0030) and NIH (DA021492 and NS007251).

Attached Files

Accepted Version - nihms75830.pdf

Supplemental Material - DREn08_supp.pdf

Files

nihms75830.pdf
Files (6.6 MB)
Name Size Download all
md5:5cf9f8a786eb97cd006fde124eb582d2
5.4 MB Preview Download
md5:97d0768b2f25738cd41dd2c641665d1f
1.2 MB Preview Download

Additional details

Created:
August 22, 2023
Modified:
October 17, 2023